Physician VersionPatient Version

Protocol No.Principal InvestigatorPhaseAge GroupScopeSecondary Protocol No.Status
OSU-10151Elder, JamesIAdultLocalOpen

Adapted from the National Cancer Institute's Physician Data Query (PDQ®) Cancer Clinical Trials (


Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recurrent High-grade Gliomas
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas


This study is being done to evaluate the toxicity and safety of carboplatin administered by convection enhanced delivery into the tumor in patients with high grade glial neoplasms. This study is a dose escalating study, (the dose of the study drug is increased at set time points). Carboplatin is in a class of drugs known as platinum-containing compounds; it slows or stops the growth of cancer cells in your body. Convection enhanced delivery involves placing one or more catheters into the brain and delivering chemotherapy through those catheters directly into the brain

To view the NCI PDQ information for this trial, click here

To view the information for this trial, click here

Detailed Description/Objectives


I. Establish the maximum tolerated dose and define the toxicity profile of carboplatin delivered intracerebrally via convection enhanced delivery (CED) for patients with high grade glial neoplasms.


I. Examine the efficacy as defined by six-month progression free survival (PFS), median progression free survival, overall survival, and the radiographic response rate.

II. Evaluate the drug distribution.

OUTLINE: This is a phase I, dose-escalation study.

Patients undergo craniotomy and then receive carboplatin intracerebrally via convection-enhanced delivery (CED) over 72 hours.


Inclusion Criteria:

Exclusion Criteria:

Applicable Disease Sites

Brain and Central Nervous System

Participating Institutions

James Cancer Hospital
OSU Medical Center


Jill Brown